Fig. 3: Better metabolic adaptations by iU87MG.

a U87MG and iU87MG cells were kept in selective metabolic stress conditions separately, such as depletion of serum, glucose, and pyruvate, along with glucose and pyruvate together for 72 h. Representative phase-contrast images showing better survivability in iU87MG in all the deprived conditions compared to U87MG. b Cell cycle analysis of U87MG and iU87MG kept under selective metabolic-depleted conditions demonstrated higher cell death in U87MG, indicating better metabolic stress adaptability of iU87MG cells. c Representative phase-contrast images showing neurospheres-like morphology upon the hypoxic condition in U87MG and both in normoxic and hypoxic conditions in iU87MG. d The expression profile of GSCs markers (CD133-APC, CD90-PECy5, and CD117-PE) in U87MG and iU87MG under normoxic (N) and hypoxic (H) conditions as assessed by flow cytometry. e Representative immunoblots representing the status of pluripotent stem cell markers (Oct4, Sox2, and Nanog), and HIF-1α and HIF-1β upon additional hypoxic stress in both U87MG and iU87MG. β-actin served as a loading control. f Schematic representation of metabolic and hypoxic stress adaptation of iU87MG. Results represent mean ± SD from three independent experiments